Alumis (ALMS) Return on Capital Employed (2024 - 2025)
Alumis (ALMS) reported Return on Capital Employed of 14.04% for Q4 2025, up 7825.0% year-over-year from 0.18% in Q4 2024, and up 85.09% quarter-over-quarter from 94.2% in Q3 2025.
Alumis (ALMS) Return on Capital Employed (2024 - 2025) Analysis & Trends
Alumis (ALMS) has 2 years of Return on Capital Employed data on file, last reported at 14.04% in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 14.04%, up 7825.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 14.04% (up 7825.0% YoY), and the FY2025 annual result was 17.45%, up 16550.0% from the prior year.
- Return on Capital Employed grew to 14.04% in Q4 2025 per ALMS's latest filing, from 94.2% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 14.04% in Q4 2025 and troughed at 147.36% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | -14.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.04% |
| Sep 30, 2025 | -94.20% |
| Jun 30, 2025 | -125.26% |
| Mar 31, 2025 | -147.36% |
| Dec 31, 2024 | -92.29% |
| Sep 30, 2024 | -79.34% |